1. Background {#sec1}
=============

Valve diseases continue to occur in many patients with significant morbidity and mortality. The age-adjusted prevalence of moderate or severe valve diseases was estimated at 2.5% \[[@B1]\]. Calcific aortic valve disease (CAVD) is the most common valve heart disease in the elderly and a leading cause of aortic stenosis \[[@B2]\]. In developing countries, CAVD represents a major cause for surgical valve replacement \[[@B3]\]. As a result of rising life expectancy and ageing populations, the burden of CAVD will significantly increase in the near future.

While CAVD was originally thought to be a degenerative process with passive deposition of calcium phosphate in the valve occurring with age, it now appears to be a complex and actively regulated progress mediated by inflammation, cell apoptosis, lipid deposition, renin-angiotensin system activation, extracellular matrix remodeling, and bone formation \[[@B4]--[@B6]\]. To better monitor progression of CAVD and identify the most appropriate instances for surgical intervention, biomarkers can be serially monitored. Such biomarkers would represent objective laboratory measurements, as older patients with CAVD might have atypical symptoms associated with comorbidities such as pulmonary disease or orthopaedic disabilities \[[@B7], [@B8]\].

MicroRNAs (miRNAs, miRs) are endogenous, small, single-stranded, 21--25 nucleotide noncoding RNAs, regulating target gene expressions by hybridizing to messenger RNAs (mRNAs). An individual miRNA is able to target tens to hundreds of genes while a single gene can also be targeted by lots of miRNAs \[[@B9]\]. Since miRNAs play critical roles in many physiological processes, increasing reports indicate that a distinct pattern of altered miRNA expressions may be linked to specific disease processes \[[@B10]--[@B15]\]. We previously reported the miRNA expression signature in degenerative aortic stenosis \[[@B14]\]. In this study, we explored the miRNA expression signature in CAVD.

2. Materials and Methods {#sec2}
========================

2.1. Tissue Sample Collection and RNA Isolation {#sec2.1}
-----------------------------------------------

This study was officially approved by the Ethics Committees of the First Affiliated Hospital of Nanjing Medical University and conformed to the principles outlined in the Declaration of Helsinki. All written informed consent was obtained from patients, and parents where applicable. Tissue samples from four healthy subjects were collected from prospective multiorgan donors in cases because of technical reasons that prevented transplantation, while stenotic aortic valve samples were obtained from four patients who underwent surgical valve replacement for aortic stenosis. All samples were examined by gross examination, and microscopic examination of hematoxylin and eosin-stained cryosections was conducted to confirm the presence/absence of CAVD. Tissue samples harvested from subject donors were snap-frozen in liquid nitrogen, and RNA was then isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s instructions.

2.2. miRNA Microarray Analysis {#sec2.2}
------------------------------

Total RNAs were isolated from heart tissues using mirVana™ RNA Isolation Kit, quantified by NanoDrop ND-2100 (Thermo Scientific), and controlled for RNA integrity using Agilent Bioanalyzer 2100 (Agilent Technologies) according to the manufacturer\'s instructions. miRNA profiling was performed with OE Biotech\'s (Shanghai, China) miRNA microarray service. The arrays from the control group are the same as we previously used \[[@B14]\].

2.3. Bioinformatic Analysis {#sec2.3}
---------------------------

TargetScan, PITA, and microRNAorg 3-way databases were used to identify potential human miRNA target genes and a Venn diagram was made to provide relations among the 3 databases. DIANA tool miRPath v2.0, a web-based analysis tool, was used for pathway enrichment analysis for the miRNA set identified \[[@B16]\]. DIANA tool miRPath assigns Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway with the significance level determined by the number of target genes affected by the identified microRNAs.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Independent Student\'s *t*-test was used to determine whether there were any significant differences between the miRNA expression profiles between two groups. *P* values less than 0.05 (*P* \< 0.05) were considered to be statistically significant. Significant data were further analyzed by clustering, and the expression profiles were visualized with GeneSpring 10.0 (Agilent Technology).

3. Results {#sec3}
==========

3.1. Principal Component Analysis of miRNA Expression Profiles {#sec3.1}
--------------------------------------------------------------

Principal component analysis (PCA) is a mathematical algorithm that reduces the dimensionality of the data while retaining most of the variation in the data set \[[@B17]\]. Dots in two colors separated in two axes based on the differences of the data, suggesting that samples in this study were prepared appropriately and could be grouped as CAVD or healthy control ([Figure 1](#fig1){ref-type="fig"}).

3.2. Unsupervised Hierarchical Cluster Analysis of miRNA Microarray Data {#sec3.2}
------------------------------------------------------------------------

miRNA arrays identified 92 miRNAs with a statistically significant differential expression of 2.0-fold or greater in CAVD samples relative to normal controls. Fifty-three miRNAs were underexpressed and 39 were overexpressed in aortic tissue from CAVD patients ([Table 1](#tab1){ref-type="table"}). Unsupervised hierarchic clustering of the two groups was performed on the 92 differently expressed miRNAs and displayed as heatmap ([Figure 2](#fig2){ref-type="fig"}).

3.3. Target Genes Analysis {#sec3.3}
--------------------------

MicroRNAorg, TargetScan, and PITA were used to predict the targets of differentially expressed miRNAs in CAVD samples. A Venn diagram was made to highlight the relations among the three databases. There are 8717 genes overlapping by all three sets, which are most likely to be targets of miRNAs in patients with CAVD ([Figure 3](#fig3){ref-type="fig"}).

3.4. DIANA miRNA Pathway Analysis {#sec3.4}
---------------------------------

To better understand the putative mechanisms underlying CAVD, we used DIANA-miRPath (v2.0), a web-based server developed to identify the potential cellular pathways regulated by microRNAs. We first evaluated downregulated miRNAs in CAVD samples compared to control samples. The potential affected pathways included the following: cell cycle, PI3K-Akt signaling pathway, ECM-receptor interaction, HIF-1 signaling pathway, p53 signaling pathway, ErbB signaling pathway, Neurotrophin signaling pathway, focal adhesion, and DNA replication ([Table 2](#tab2){ref-type="table"}). Upregulated miRNAs were also used to generate the potential affected pathways by DIANA-miRPath and identified p53 signaling pathway, HIF-1 signaling pathway, valine, leucine, and isoleucine biosynthesis, ErbB signaling pathway, cell cycle, mTOR signaling pathway, MAPK signaling pathway, PI3K-Akt signaling pathway, Wnt signaling pathway, synthesis and degradation of ketone bodies, TGF-beta signaling pathway, basal transcription factors, glycerophospholipid metabolism, hypertrophic cardiomyopathy (HCM), focal adhesion, circadian rhythm, mismatch repair, lysine degradation, and butanoate metabolism ([Table 3](#tab3){ref-type="table"}).

4. Discussion {#sec4}
=============

miRNAs have been shown to be critical regulators in cardiovascular diseases \[[@B18]--[@B25]\]. However, there are no reports revealing distinct miRNA expression signatures in the CAVD patients and healthy controls. In this study, we identified global changes in the miRNA expression profile in CAVD and healthy control. Calcific aortic valve stenosis is characterized by lipid accumulation, inflammation, formation of plaque neovessels, hemorrhages, neointimal formation, vascular fibrosis, and ectopic calcification \[[@B4], [@B26]\]. Previous studies have shown that miRNAs play crucial roles in those processes such as angiogenesis, fibrogenesis, proliferation, and apoptosis \[[@B9]\].

miR-126 is one of the most abundantly expressed microRNAs in endothelial cells (ECs) \[[@B27]\]. Upregulation of miR-126 increases EC survival, decreases EC apoptosis, and prevents reactive oxygen species (ROS) mediated endothelial damage \[[@B28]\]. Our findings of decreased miR-126 in CAVD may suggest a detrimental effect in human calcific aortic valve.

The differentially expressed miRNAs identified in the current study also included many profibrotic miRNAs such as miR-21 and miR-125b that might contribute to CAVD by promoting fibrosis. Several expression profiling studies identify that increased level of miR-21-5p in cardiac fibroblasts promotes cardiac fibrosis via its target genes: phosphatase and tensin homolog (PTEN) \[[@B29]\] and Sprouty-1 (*Spry*1) \[[@B30]\]. Additionally, miR-125b is a novel regulator of cardiac fibrogenesis, proliferation, and fibroblast-to-myofibroblast transition. Nagpal et al. demonstrated the upregulation of miR-125b in fibrotic human heart and murine models of cardiac fibrosis \[[@B31]\].

Interestingly, our miRNA array data revealed that several members of the let-7 (let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, and let-7g) were downregulated in calcific aortic valve. Let-7g targets the genes related to vascular smooth muscle cell (VSMC) functions, including ROS, autophagy-related proteins (expression of beclin-1, LC3-II, and Atg5), and apoptosis-related proteins (expression of caspase-3, Bax, Bcl-2, and Bcl-xL) \[[@B32]\]. Let-7 family members might directly influence aortic valve sclerosis by regulating the proliferation, migration, autophagy, and apoptosis of VSMC, which have been implicated in the progression of CAVD \[[@B4], [@B26]\].

The abnormal expression of miR-21-5p was found in many cardiovascular diseases \[[@B33]\]. Programmed cell death 4 (PDCD4) is identified as a direct target gene of miR-21-5p. It has been reported that miR-21-5p prevented cardiomyocyte apoptosis in ischaemia/reperfusion heart model through PDCD4 repression \[[@B34]\]. Furthermore, miR-21/PDCD4 pathway was proved to be involved in cardiac valvulogenesis by regulating endothelial cell migration \[[@B35]\]. In our work, miR-21-5p was upregulated in calcific aortic valve which indicates that miR-21-5p might take part in CAVD. However, the effects and mechanisms of miR-21-5p on calcific aortic valve are still to be investigated in further studies.

A comprehensive knowledge of miRNA expression is essential to improve our understanding of this disease. This study provides the first evidence that there exists a distinct miRNA expression signature in individuals with CAVD, as compared to healthy controls. There are 92 differently expressed miRNAs in the CAVD patients compared with healthy controls by miRNA arrays. PCA and unsupervised hierarchical clustering with these miRNAs demonstrates that this profile could accurately classify the samples according to their disease status. Moreover, bioinformatic tools indicate that the differential expression of miRNAs could be linked to several targets and pathways.

As a limitation of our study, the exact pathways by which dysregulated miRNAs cause CAVD in human remain elusive. Further studies are required to fully characterize the function of candidate miRNAs.

5. Conclusions {#sec5}
==============

Taken together, the current study provides insight into the importance of microRNA expression signature in CAVD. A deeper understanding of the molecular alternations in CAVD may provide potential targets for future clinical applications.
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![PCA of the miRNA profiles in CAVD tissue samples and control subjects. Red dots represent samples from control group, while blue dots represent samples from CAVD group.](BMRI2017-4820275.001){#fig1}

![Unsupervised hierarchical clustering identified two distinct groups (CAVD versus control) based on their miRNA expression profile. Sample names are listed at top. The names of the significantly altered (*P* value \< 0.05) miRNAs are shown at right. Ninety-two miRNAs were expressed differently between the two groups.](BMRI2017-4820275.002){#fig2}

![The red, green, and blue sets stand for target genes predicted by database microRNAorg, TargetScan, and PITA, respectively.](BMRI2017-4820275.003){#fig3}

###### 

Fifty-three underexpressed and 39 overexpressed miRNAs in aortic tissue from CAVD patients compared to the control group.

  Systematic name     *P* value   Fold change   Regulation
  ------------------- ----------- ------------- ------------
  hsa-miR-3656        0.011202    2.0143232     Up
  hsa-miR-765         0.033639    2.0401733     Up
  hsa-miR-2861        0.008741    2.0782373     Up
  hsa-miR-663a        0.00633     2.0819619     Up
  hsa-miR-1246        0.027045    2.1549542     Up
  hsa-miR-3141        0.002969    2.2772849     Up
  hsa-miR-125a-3p     0.012002    2.3428166     Up
  hsa-miR-4327        0.004807    2.367507      Up
  hsa-miR-638         0.002785    2.3686504     Up
  hsa-miR-4270        0.030574    2.4421182     Up
  hsa-miR-642b-3p     0.034575    2.5763547     Up
  hsa-miR-513a-5p     0.007538    2.6546612     Up
  hsa-miR-483-5p      0.008099    2.655595      Up
  hsa-miR-3679-5p     0.004016    2.7413363     Up
  hsa-miR-3648        0.017053    2.8097122     Up
  hsa-miR-30c-1-3p    7.64E-04    2.893416      Up
  hsa-miR-1275        0.005457    2.9556682     Up
  hsa-miR-513b        0.020604    3.4257321     Up
  hsa-miR-1972        0.011389    3.689852      Up
  hsa-miR-3138        0.004076    3.974949      Up
  hsa-miR-3663-3p     0.005874    4.314916      Up
  hsa-miR-21-5p       0.003826    4.317176      Up
  hsa-miR-718         0.031718    4.957687      Up
  hsa-miR-630         0.001304    7.3841376     Up
  hsa-miR-575         0.001586    10.079804     Up
  hsa-miR-3934        0.048827    13.458452     Up
  hsa-miR-143-5p      0.033632    16.2909       Up
  hsa-miR-3131        0.047501    22.065104     Up
  hsa-miR-125b-1-3p   0.00519     23.412596     Up
  hsa-miR-625-3p      0.005867    23.648891     Up
  hsa-miR-1471        0.035145    25.31259      Up
  hsa-miR-4314        0.032125    27.92129      Up
  hsa-miR-636         0.00923     28.36478      Up
  hsa-miR-3945        0.018336    38.864952     Up
  hsa-miR-3610        0.014352    49.196358     Up
  hsa-miR-1182        1.46E-05    73.30232      Up
  hsa-miR-3713        2.44E-05    117.90961     Up
  hsa-miR-21-3p       5.95E-05    149.08258     Up
  hsa-miR-516a-5p     2.88E-05    155.79349     Up
  hsa-miR-654-3p      0.002559    2.0230756     Down
  hsa-miR-93-5p       0.020279    2.0238087     Down
  hsa-miR-320d        0.038247    2.052202      Down
  hsa-miR-381         0.035566    2.0584567     Down
  hsa-miR-214-3p      0.011756    2.0957778     Down
  hsa-miR-125b-5p     0.036771    2.1063256     Down
  hsa-miR-361-3p      0.036059    2.1256602     Down
  hsa-miR-29c-3p      0.009743    2.1358023     Down
  hsa-miR-495         0.001289    2.1425073     Down
  hsa-miR-374a-5p     0.01904     2.1439137     Down
  hsa-miR-20b-5p      0.027368    2.1694279     Down
  hsa-miR-382-5p      0.043289    2.1756916     Down
  hsa-miR-4324        0.039752    2.178068      Down
  hsa-miR-25-3p       0.004579    2.1911306     Down
  hsa-miR-100-5p      0.035509    2.1913323     Down
  hsa-miR-193b-3p     0.022676    2.191656      Down
  hsa-miR-107         0.007782    2.2016506     Down
  hsa-miR-660-5p      8.68E-04    2.2094207     Down
  hsa-miR-103a-3p     0.020178    2.2370007     Down
  hsa-miR-195-5p      0.049708    2.3292358     Down
  hsa-miR-299-5p      0.002066    2.3574395     Down
  hsa-miR-487b        7.71E-04    2.422462      Down
  hsa-miR-128         0.022531    2.4691415     Down
  hsa-miR-181d        0.019566    2.5412066     Down
  hsa-miR-374b-5p     0.038373    2.5474217     Down
  hsa-let-7b-5p       0.042981    2.6197023     Down
  hsa-miR-140-5p      0.005972    2.639281      Down
  hsa-let-7g-5p       0.02818     2.7145965     Down
  hsa-miR-151a-5p     0.010444    2.7681546     Down
  hsa-miR-532-5p      0.020008    2.7994845     Down
  hsa-miR-26b-5p      0.025414    2.8088717     Down
  hsa-miR-30e-3p      0.020305    2.8739653     Down
  hsa-miR-140-3p      0.040144    2.8943768     Down
  hsa-miR-29c-5p      0.004665    2.9975233     Down
  hsa-miR-181c-5p     0.015322    3.0353231     Down
  hsa-miR-204-5p      0.044941    3.0471704     Down
  hsa-let-7d-5p       0.025658    3.0987353     Down
  hsa-miR-98          0.027495    3.2012997     Down
  hsa-miR-10a-5p      0.019225    3.3482268     Down
  hsa-let-7f-5p       0.037282    3.4332418     Down
  hsa-let-7e-5p       0.018337    3.6489105     Down
  hsa-let-7a-5p       0.029403    3.6912477     Down
  hsa-miR-99a-5p      0.035923    3.8172672     Down
  hsa-let-7c          0.032672    3.9863558     Down
  hsa-miR-126-3p      0.026073    4.528461      Down
  hsa-miR-29b-1-5p    0.006566    15.589992     Down
  hsa-miR-181c-3p     0.008219    16.225191     Down
  hsa-miR-194-5p      0.011511    20.940771     Down
  hsa-miR-335-5p      0.006273    36.750603     Down
  hsa-miR-126-5p      0.015298    38.692142     Down
  hsa-miR-505-5p      1.18E-05    42.592148     Down
  hsa-miR-625-5p      0.008835    43.434204     Down
  hsa-miR-200b-3p     1.60E-06    70.24472      Down

###### 

The pathways incorporated by downregulated microRNAs in CAVD.

  KEGG pathway                     *P* value      Genes   miRNAs
  -------------------------------- -------------- ------- --------
  Cell cycle                       \<1*E* − 16    48      19
  PI3K-Akt signaling pathway       2.22*E* − 16   95      17
  ECM-receptor interaction         1.85*E* − 12   9       4
  HIF-1 signaling pathway          8.63*E* − 10   30      15
  p53 signaling pathway            1.49*E* − 08   28      14
  ErbB signaling pathway           7.14*E* − 05   23      12
  Neurotrophin signaling pathway   0.00249        19      10
  Focal adhesion                   0.0029         19      6
  DNA replication                  0.013417       19      2

###### 

The pathways affected by upregulation of specific microRNAs in CAVD.

  KEGG pathway                                   *P* value      Genes   miRNAs
  ---------------------------------------------- -------------- ------- --------
  p53 signaling pathway                          5.63*E* − 09   11      2
  HIF-1 signaling pathway                        0.00023        10      2
  Valine, leucine, and isoleucine biosynthesis   0.00227        1       1
  ErbB signaling pathway                         0.003959       5       1
  Cell cycle                                     0.003959       10      2
  mTOR signaling pathway                         0.004909       6       1
  MAPK signaling pathway                         0.005193       15      2
  PI3K-Akt signaling pathway                     0.005193       17      2
  Wnt signaling pathway                          0.008586       10      1
  Synthesis and degradation of ketone bodies     0.009366       2       1
  TGF-beta signaling pathway                     0.021216       7       1
  Basal transcription factors                    0.029417       4       1
  Glycerophospholipid metabolism                 0.030271       8       1
  Hypertrophic cardiomyopathy (HCM)              0.030271       6       1
  Focal adhesion                                 0.030271       11      2
  Circadian rhythm                               0.030848       3       1
  Mismatch repair                                0.034518       2       1
  Lysine degradation                             0.038471       4       1
  Butanoate metabolism                           0.038615       3       1

Specific types of cancers and infections were not included.
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